An interventional study of MoCA Test and Laboratory tests in Chronic Kidney Disease, sponsored by Mario Negri Institute for Pharmacological Research. Not yet recruiting at 5 sites in 4 countries. Open to participants aged 40 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Mario Negri Institute for Pharmacological Research · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research — 3 open to participants now, 4 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Mario Negri Institute for Pharmacological Research.
Among the 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research, this one is the only one that started in 2027, is one of 3 with no phase, and was the 10th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 699 are open to participants now.
Browse Renal Insufficiency, Chronic studies →3 of the 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research are open now, in 4 countries. Recruiting first, the newest first:
Mario Negri Institute for Pharmacological Research · Sites in Italy
Ages 18+
Mario Negri Institute for Pharmacological Research · Sites in Italy
Ages 18+
By country, each count listing its studies:
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 73 across 2,163 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 40 across the 7 interventional studies, 60 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mario Negri Institute for Pharmacological Research is the lead sponsor of 161 studies on the registry; 38 are open to participants now.
1 of the studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07663773Mario Negri Institute for Pharmacological ResearchThyroid Hormones in CKD | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Renal Insufficiency, Chronic by Mario Negri Institute for Pharmacological Research, from their registry updates:
This tab as a report to print or save as PDF → With an account.
MOMENTUM is an investigator-initiated, multicentre, international, controlled, cross-sectional and longitudinal clinical study, which aims to evaluate the association between plasma levels of UTs and the presence and severity of cognitive impairment, and their mechanistic interplay in study participants with CKD at different disease stages.
The study consists of three main phases: a screening period, a cross-sectional (baseline) phase, and an 18-month follow-up (longitudinal phase).
Chronic kidney disease (CKD) represents a major and growing global health challenge, affecting over 800 million people worldwide across stages. Its prevalence is increasing due to rising rates of diabetes, hypertension, and obesity, the most common causes of CKD, and the disease is projected to become the fifth leading cause of death by 2040. CKD has been recently prioritized within the WHO noncommunicable diseases agenda in alignment with the United Nation's Sustainable Development Goal (SDG) 3.4 and 3.8. Beyond its direct contribution to morbidity and mortality and its established role as a major risk factor for cardiovascular disease, CKD also significantly impacts neurological health.
Cognitive impairment - particularly Mild Cognitive Impairment (MCI) - is increasingly recognized as a frequent but underexplored complication, occurring at more than twice the rate observed in age-matched individuals from the general population. MCI markedly increases the risk of progression to dementia, and is associated with substantial consequences for patients, caregivers, healthcare systems, and society, highlighting the importance of early identification and intervention.
Despite its clinical and societal importance, MCI-CKD remains an under-recognized health challenge. Its pathophysiological mechanisms are poorly understood, no specific biomarkers have been validated to support diagnosis or prognosis, and no established guidelines exist for its systematic monitoring or management. Most patients remain unaware of the condition, and healthcare providers often overlook it. This lack of awareness and diagnostic capacity hampers timely interventions, including referrals for symptomatic treatments, cognitive rehabilitation strategies, or preventive measures.
As a transitional stage preceding clinical dementia, early identification of MCI-CKD may allow nephrologists to refer patients to neurologists for symptomatic treatments and cognitive rehabilitation strategies.18 Patients diagnosed with MCI-CKD may also be referred for other interventions addressing other modifiable drivers of MCI, such as sleep, stress, dietary habits, exercise and cardiovascular disease.
Clinically, CKD is characterized by a progressive decline in kidney function, typically assessed by the glomerular filtration rate (GFR), which can be estimated through equations based on serum creatinine, cystatin C, or a combination of both (eGFR), or directly measured using exogenous filtration markers such as iohexol or iothalamate clearance (mGFR). Additional indicators of kidney damage include blood urea nitrogen (BUN) levels, the urinary albumin-to-creatinine ratio (ACR), and histological findings from kidney biopsy. However, accurately quantifying nephron loss and the extent of renal fibrosis remains challenging. As kidney function declines, disturbances develop in electrolyte, water, acid-base, and mineral homeostasis. Uremic toxins (UTs) accumulate, and renal anaemia emerges. Several CKD-related factors, including metabolic alterations, inflammation, vascular dysfunction, and UT accumulation, have been independently associated with an increased risk of cognitive impairment.
The MOMENTUM cross-sectional and longitudinal clinical study is designed to address this critical gap. By comprehensively characterizing cognitive impairment in CKD and integrating multimodal biomarkers, including circulating and microbiome-derived uremic toxins, advanced neuroimaging, and clinical assessments, it aims to improve early detection and risk stratification of MCI-CKD. This knowledge will contribute to a better understanding of disease mechanisms, support earlier diagnosis, and enable the development of targeted strategies to reduce cognitive decline and dementia burden in individuals with CKD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Specifically for CKD participants:
Specifically for controls:
Normal renal function:
Exclusion Criteria
Specifically for CKD patients:
Specifically for controls:
● Any chronic clinically significant condition, except for hypertension treated with \< 3 antihypertensive drugs.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with CKD stage G3 (eGFR 30-59 mL/min/1.73 m2), balanced between the two sub-stages G3a (eGFR 45-59 mL/min/1.73 m2) and G3b (eGFR 30-44 mL/min/1.73 m2)
Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections · Behavioral: Questionnaires · Behavioral: New MCI-CKD QoL Questionnaire
Patients with CKD stages G4-G5 without kidney replacement therapy (eGFR \< 30 mL/min/1.73 m2)
Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections · Behavioral: Questionnaires · Behavioral: New MCI-CKD QoL Questionnaire
Patients with CKD stage G5 on chronic hemodialysis (eGFR \< 15 mL/min/1.73 m2)
Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, other sections · Behavioral: Questionnaires · Behavioral: New MCI-CKD QoL Questionnaire
Healthy controls
Behavioral: MoCA Test · Diagnostic Test: Laboratory tests · Diagnostic Test: Non-contrast-enhanced brain MRI · Behavioral: Comprehensive neuropsychological test battery · Behavioral: Kidney Disease Quality of Life Instrument (KDQOL), KDQOL-SF™ v1, first section · Behavioral: Questionnaires
Montreal Cognitive Assessment Test
The test include: local blood biochemistry, uremic toxin (UT) levels and blood-brain barrier (BBB) injury markers, urine dipstick, urine pregnancy test, morning urine sample, extracellular vesicle analysis, gut microbiome profiling
MCI-CKD-tailored brain non-contrast MRI sequences on 3T scanners, to be acquired in the following fixed order: 3D T1-weighted MPRAGE, T2 FLAIR, Multi-echo arterial spin labelling (multi-TE ASL), Diffusion MRI, Quantitative susceptibility mapping (QSM), Multi-delay arterial spin labelling, Resting-state functional MRI (rs-fMRI)
The comprehensive battery of neuropsychological tests includes: Episodic memory \[assessed through Rey Auditory Verbal Learning Test (RAVLT)\]; Processing speed and executive function \[assessed through Trail Making Test - Part A (TMT-A) and Trail Making Test - Part B (TMT-B)\]; Processing speed, attention, and working memory \[assessed through Symbol Digit Modalities Test (SDMT)\]; Language and executive function \[assessed through Verbal Fluency Test (VFT))\] Executive function assessed through Frontal Assessment Battery (FAB)\]
"Your Health" section, corresponding to the SF-12 questionnaire
Sections specific to kidney disease excluding the first section
Cognitive reserve will be assessed using the Cognitive Reserve Index questionnaire (CRIq). Symptoms of depression and anxiety will be assessed using the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 (GAD-7) questionnaire, respectively. Frailty will be evaluated using the Clinical Frailty Scale (CFS).
The new MCI-CKD-specific quality of life questionnaire developed within the MOMENTUM project
Correlation between blood levels of the 6 predefined UTs (individually and in combination) and the presence and severity of cognitive impairment, within each CKD group separately.
Correlation coefficient (e.g., Pearson's r or Spearman's rho). The coefficient is computed for each of the 6 UTs and for the combination, within each CKD group separately.
Time frame: Baseline (Visit 2, Day 0)
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2027; primary completion for Dec 2029, 32 months later.
Of 580 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 32 months is above that.
Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Mario Negri Institute for Pharmacological Research →